CRISPR, the gene-editing technology which won its creators the 2020 Nobel Prize for Chemistry, is most well-known for its ...
Cambridge-based Fulcrum Therapeutics said it will aim to launch a large clinical trial in the second half of 2026 to prove ...
Zacks Investment Research on MSN
CRISPR Therapeutics AG (CRSP) is attracting investor attention: Here is what you should know
CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...
Revvity targets 2026 growth with multiomics, AI-powered base editing, NGS newborn screening, and immunotherapy advances.
Researchers used CRISPR screening in tumor organoids and mice to identify two genes, Ctnna1 and Bcl2l13, that suppress ...
A study identified two key genes (CTNNA1 and BCL2L13) as suppressors in spread of colorectal cancer, revealing new strategies ...
Poster presentation highlights promising results from Phase 1b/2 TENACITY-01 study of CTD402 in T-Cell and myeloid leukemiasFindings underscore ...
Zai Lab Limited today announced the dosing of the first participant in a global Phase 1/1b clinical trial evaluating the safety, tolerability, pharmacokinetics, and efficacy of ZL-1503, a potential ...
Data presented at ASH suggest that the CRISPR therapy could provide a one-time functional cure in children as young as 5 ...
Data Demonstrate Potent in vivo Gene Editing of Hematopoietic Stem Cells (HSCs) in the Bone Marrow with Systemic Delivery in Preclinical Murine ...
Altair, a global leader in computational intelligence and now part of leading technology company, Siemens, announced the latest updates to HyperWorks® 2026 software. With significant advances in AI, ...
Biomaterials have evolved from passive structural scaffolds to active intelligent systems that dynamically interact with the biological environment. Recent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback